62143-69-5

Usage

InChI:InChI=1/C15H11NO3/c17-14(18)9-10-6-7-12-13(8-10)19-15(16-12)11-4-2-1-3-5-11/h1-8H,9H2,(H,17,18)

Upstream product

• 93-89-0 benzoic acid ethyl ester 
• 51234-51-6 6-bromomethyl-2-phenyl-benzooxazole 
• 3743-11-1 N-(2-hydroxy-4-methylphenyl)benzamide 
• 65-85-0 benzoic acid 
• 353525-11-8 methyl (4-amino-3-hydroxyphenyl)acetate 
• 2835-98-5 2-Hydroxy-4-methylanilin 
• 62143-68-4 (2-phenyl-benzooxazol-6-yl)-acetonitrile 
• 98-88-4 benzoyl chloride 
• 14016-00-3 6-methyl-2-phenylbenzoxazole 

Downstream Products

• 51234-52-7 (2-phenyl-benzooxazol-6-yl)-acetic acid ethyl ester 
• 1361330-52-0 trans-4-[1-[(2-phenyl-6-benzoxazolyl)acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid 
• 62143-73-1 2-(2-phenyl-benzooxazol-6-yl)-propylamine 
• 51234-54-9 2-(2-phenyl-benzooxazol-6-yl)-propan-1-ol 
• 51234-94-7 2-(2-phenyl-benzooxazol-6-yl)-ethanol 
• 51234-53-8 2-(2-phenyl-benzooxazol-6-yl)-propionic acid ethyl ester 
• 51234-55-0 2-(2-phenyl-benzooxazol-6-yl)-propionamide 
• 62143-72-0 2-(2-phenyl-benzooxazol-6-yl)-propionitrile 
• 51234-58-3 2-(2-phenyl-benzooxazol-6-yl)-propionic acid 

Relevant academic research and scientific papers

Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6- benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist

For the purpose of obtaining orally potent VLA-4 inhibitors, we have carried out structural modification of the (N′-phenylureido)phenyl group in compound 1, where the group was found to be attributed to poor pharmacokinetic profile in our previous research. Through modification, we have identified several compounds with both potent in vitro activity and improved oral exposure. In particular, compound 7e with 7-fluoro-2-(1-methyl-1H-indol-3- yl)-1,3-benzoxazolyl group as a novel replacement of the (N′-phenylureido) phenyl group significantly inhibited eosinophil infiltration into bronchoalveolar lavage fluid at 15 mg/kg in an Ascaris-antigen-induced murine bronchial inflammatory model, and its efficacy was comparable to that of the anti-mouse α4 antibody (R1-2).

Benzoxazole derivatives in treating inflammation, pain and fever

The invention provides novel 5- and 6-benzoxazolyl alkanoic acids, optionally substituted in the 2-position, and derivatives thereof which possess anti-inflammatory, anti-pyretic and analgesic activity. Also provided is a process for preparing such compounds by cyclising an appropriately substituted o-aminophenol and, if necessary, converting the resultant benzoxazole to the desired compound.